HER-2 profiling and targeting in prostate carcinoma: A phase II trial of trastuzumab alone and with paclitaxel Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma
  • Gene Expression Regulation, Neoplastic
  • Paclitaxel
  • Prostatic Neoplasms
  • Receptor, ErbB-2

abstract

  • Trastuzumab is not effective as a single agent for the treatment of patients with AI HER-2 negative tumors. HER-2 expression varies by clinical state in patients with prostate carcinoma: Accurate HER-2 profiling requires sampling metastatic tissue in patients with metastatic disease. Further development of trastuzumab for the treatment of patients with metastatic prostate carcinoma is not feasible until more reliable and practical methods of sampling metastatic disease are developed to identify patients with HER-2 positive tumors.

publication date

  • February 15, 2002

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.10339

PubMed ID

  • 11920466

Additional Document Info

start page

  • 980

end page

  • 6

volume

  • 94

number

  • 4